The Use of Lexipafant in the Treatment of Acute Pancreatitis

  • C. McKay
  • F. J. M. Curran
  • C. E. Sharples
  • C. A. Young
  • J. N. Baxter
  • C. W. Imrie
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 416)


Acute pancreatitis is a common condition which may varies in severity from a mild, self-limiting illness to a fulminating, rapidly fatal condition. Two phases of illness are recognised. Initially, patients have a systemic illness characterised by varying degrees of organ failure. In the second and third weeks of the illness, the main problems relate to local, pancreatic complications.


Acute Pancreatitis Tumour Necrosis Factor Alpha Platelet Activate Factor Severe Acute Pancreatitis Experimental Pancreatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Frey CF, Wong HN, Hickman D, Pullos T. Toxicity of haemorrhagic ascitic fluid associated with haemorrhagic pancreatitis. Arch Surg 1982; 117: 401–404.PubMedCrossRefGoogle Scholar
  2. 2.
    Ohlssen K, Tegner H. Experimental pancreatitis in the dog. Demonstration of trypsin in ascitic fluid, lymph and plasma. Scand J Gastroenterol 1973; 8: 129–133.Google Scholar
  3. 3.
    Amundsen E, Ofstad E, Hagen P-O. Experimental acute pancreatitis in dogs. Hypotensive effect induced by peritoneal exudate. Scand J Gastroenterol 1968; 3: 659–664.PubMedGoogle Scholar
  4. 4.
    Balldin G, Ohlsson K. Demonstration of pancreatic protease-antiprotease complexes in the peritoneal fluid of patients with acute pancreatitis. Surgery I979; 85: 451–6.Google Scholar
  5. 5.
    Wilson C, Shenkin A, Imrie C. Role of the protease-antiprotease balance in peritoneal exudate during acute pancreatitis. Br J Surg 1991; 78: 78–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Medical Research Council of the United Kingdom. Death from acute pancreatitis: Multicentre trial of glu-cagon and aprotinin. Lancet 1977;ii:632–635.Google Scholar
  7. 7.
    Imrie CW, Benjamin S, Ferguson JC, McKay AJ, MacKenzie I, O’Neill J, Blumgart LH. A single-centre double-blind trial of Trasylol in primary acute pancreatitis. Br J Surg 1978; 65: 337–341.PubMedCrossRefGoogle Scholar
  8. 8.
    Leese T, Holliday M, Heath D, Hall AW, Bell PRF. Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Br J Surg 1987; 74: 907–911.PubMedCrossRefGoogle Scholar
  9. 9.
    Leese T, Thomas WM, Holloday M, Attard A, Watkins M, Neoptolemos JP, Hall C. A multicentre controlled clinical trial of high-volume fresh frozen plasma in prognostically severe acute pancreatitis. Ann R Coll Surg Eng 1991; 73: 207–214.Google Scholar
  10. 10.
    Buehler M, Malfertheiner P, Uhl W, Scholmerich J, Stockman F, Adler G, Gaus W, Rolle K, Beger HG and the German Pancreatic Study Group. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993; 104: 1165–1170Google Scholar
  11. 11.
    Bradley EL, Hall JR, Lutz J, Hamner L, Lattouf O. Haemodynamic consequences of severe pancreatitis. Ann Surg 1983; 198: 130–133.PubMedCrossRefGoogle Scholar
  12. 12.
    Beger HG, Bittner R, Buehler M, Hess W, Schmitz JE. Haemodynamic data pattern in patients with acute pancreatitis. Gastroenterology I986; 90: 74–79Google Scholar
  13. 13.
    Tracey KJ, Lowrey SF. The role of cytokine mediators in septic shock. Adv Surg 1990; 23: 21–56.PubMedGoogle Scholar
  14. 14.
    Braquet P, Paubert-Braquet M, Bourgain RH, Bussolino F, Hosford D. PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischaemia and graft rejection. J Lipid mediators 1989; 1: 75–112.Google Scholar
  15. 15.
    Rinderknecht H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation? Int J Pancreatology 1988; 3: 105–112.Google Scholar
  16. 16.
    Heath DI, Cruickshank A, Gudgeon M, Jehanli A, Shenkin A, Imrie CW. Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. Gut 1993; 34: 41–45.PubMedCrossRefGoogle Scholar
  17. 17.
    Leser H-G, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, Ruckauer K, Andreesen R, Farthmann EH, Scholmerich J. Evaluation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 101: 782–785.PubMedGoogle Scholar
  18. 18.
    Viedma JA, Perez-Mateo M, Dominguez JE, Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut 1992; 33: 1264–1267.PubMedCrossRefGoogle Scholar
  19. 19.
    Banks RE, Evans SW, Alexander D, McMahon MJ, Whicher JT. Is fatal acute pancreatitis a consequence of excessive leucocyte stimulation? The role of tumour necrosis factor. Cytokine I991; 3: 12–16.Google Scholar
  20. 20.
    Exley AR, Leese T, Holloday MP, Swann RA, Cohen J. Endotoxaemia and serum tumour necrosis factor as prognostic markers in severe acute pancreatitis. Gut 1992; 33: 1126–1128PubMedCrossRefGoogle Scholar
  21. 21.
    Kriegler M, Perez C, Defay K. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein. Ramifications for the complex physiology of TNFa. Cell 1988; 53: 45–53PubMedCrossRefGoogle Scholar
  22. 22.
    Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991; 5: 2567–2574.PubMedGoogle Scholar
  23. 23.
    James K, van de Haan J, Lens S, Farmer F. Preliminary studies on the interaction of TNFa and IFN with alpha 2 macroglobulin. Immunology Letters 1992; 32: 49–58.PubMedCrossRefGoogle Scholar
  24. 24.
    McIntyre CA, Chapman K, Reeder S, Dorreen MS, Bruce L, Rodgers S, Hayat K, Schreenivasan T, Sheridan E, Hancock BW, Rees RC. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants. Eur J Cancer 1992; 28: 58–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Blick M, Sherwin S, Rosenbum M et al Phase 1 study of recombinant tumour necrosis factor in cancer patients. Cancer Res 1987; 47: 2986–2989PubMedGoogle Scholar
  26. 26.
    McKay C, Baxter JN, Imrie CW. Systemic complications in acute pancreatitis are associated with increased cytokine release by monocytes. Digestion 1994; 55: 316–7.Google Scholar
  27. 27.
    Bonavida B, Mencia-Huerta JM, Braquet R. Effect of platelet activating factor (PAF) on monocyte activation and production of tumour necrosis factor (TNF). J Allergy Appl Immunol 1989; 88: 157–160.CrossRefGoogle Scholar
  28. 28.
    Sun X, Hsueh W. Bowel necrosis induced by tumour necrosis factor in rats is mediated by platelet activating factor. J Clin Invest 1988; 81: 1328–1331.PubMedCrossRefGoogle Scholar
  29. 29.
    Konturek SJ, Dembinski A, Konturek PJ, Warzecha Z, Jaworek J, Gustaw P, R Tomaszewska R, Stachura J. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut 1992; 33: 1268–1274.PubMedCrossRefGoogle Scholar
  30. 30.
    Emanuelli G, Montrucchio G, Gaia E, Dughera L, Corvetti G, Gubetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Path 1989; 134: 315–326.PubMedGoogle Scholar
  31. 31.
    Zhou W, Mcollum MO, Levine BA, Olson MS. Role of platelet activating factor in pancreatitis-associated lung injury in the rat. Am J Path 1992; 140: 971–979.PubMedGoogle Scholar
  32. 32.
    Dabrowski A, Gabryelewicz A, Chyczewski L. The effect of platelet activating factor antagonist (BN 52021) on ceuelin-induced acute pancreatitis with reference to oxygen radicals. Int J Pancreatol 1991; 8: 1–11.PubMedGoogle Scholar
  33. 33.
    Guillermo A, Lopez Farre A, Gomez Garre DN, Novo C, Romeo JM, Braquet P, Lopez-Novoa JM. Role of platelet activating factor in haemodynamic derangements in an acute rodent pancreatic model. Gastroenterology 1992; 102: 181–187.Google Scholar
  34. 34.
    Chang SW, Fedderson CO, Henson PM, Voelkel NF. Platelet activating factor mediates haemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987; 79: 1498–1509.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • C. McKay
    • 1
  • F. J. M. Curran
    • 1
  • C. E. Sharples
    • 1
  • C. A. Young
    • 1
  • J. N. Baxter
    • 1
  • C. W. Imrie
    • 1
  1. 1.Departments of SurgeryGlasgow Royal Infirmary and Western InfirmaryGlasgowScotland

Personalised recommendations